Table 5 Clinicopathological characteristics of the patients included in the study.
Variables | n = 100 |
|---|---|
Epidemiological features | |
Age at diagnosis [median, (range)] | 65.5 (21–90) |
Age at diagnosis (%) | |
<40 | 6 |
40–65 | 44 |
>65 | 50 |
Sex (%) | |
Male | 53 |
Female | 47 |
Clinical melanoma features | |
Anatomic site (%) | |
Head/neck | 16 |
Upper extremities | 16 |
Trunk | 42 |
Lower extremities | 18 |
Acral | 8 |
Sun related site (%) | |
Non exposed | 21 |
Occasionally exposed | 63 |
Usually exposed | 16 |
Pathological melanoma features | |
Histological subtype (%) | |
LMM | 10 |
SSM | 68 |
NM | 14 |
AML | 8 |
Breslow thickness (mean (±SD)) | 1.9 ± 2.1 |
Breslow thickness (%) | |
<1 mm | 47 |
1–2 mm | 21 |
2–4 mm | 19 |
>4 mm | 13 |
Ulceration (%) | |
No | 74 |
Yes | 26 |
Regression (%) | |
No | 52 |
<50% | 41 |
>50% | 7 |
Mitoses/mm2 (%) | |
<1 | 48 |
>1 | 52 |
Growth rate (%) | |
SGM | 76 |
FGM | 24 |
Tumor stage (%) | |
Localized (I–II) | 75 |
Locoregional and metastatic disease (III–IV) | 25 |
Months follow-up [median, (range)] | 32 (6–121) |
Clinical outcome (%) | |
Stable disease | 81 |
Relapse (locoregional vs distant metastasis) | 8 |
Exitus | 11 |
